Nancy L Allbritton

Irvine, CA, United States of America

Nancy L Allbritton

This inventor holds 28 USPTO granted patents and 14 published patent applications and 4 EPO patents, primarily in Cell Culture Technology. Top assignees: The University of North Carolina at Chapel Hill, University of California, Cell Microsystems, Inc.. Active years: 2000-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nancy L Allbritton. Retrieved from https://idiyas.com/inventor/nancy-l-allbritton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 

% Patents Active = 89.3

 

Average Co-Inventor Count = 3.7

ph-index = 9

Forward Citations = 180(Granted Patents)


Location History:

  • Irvine, CA (US) (2000 - 2013)
  • Chapel Hill, NC (US) (2014 - 2024)
  • Seattle, WA (US) (2024)

Company Filing History:


Years Active: 2000-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Intestinal Crypts
Polymer Scaffolds
Cell Sorting
Hypoxic Conditions
Tissue Constructs
Micro-Molded Structures
Biochemical Analysis
Laser Lysis
Enzymatic Activity
Single Cell Collection
Photosensitized Resin
Multiplexed Assays
28 patents (USPTO):Explore Patents

Title: Innovations of Nancy L. Allbritton in the Field of Biomedical Engineering

Introduction

Nancy L. Allbritton is a notable inventor based in Irvine, California, recognized for her significant contributions to the field of biomedical engineering. With a remarkable portfolio of 24 patents, her innovative work focuses on developing advanced techniques and devices for cell culture and tissue engineering.

Latest Patents

Among her latest patents, two stand out for their potential impact on research in intestinal biology and cell culture technologies. The first patent is titled "Formation of arrays of planar intestinal crypts possessing a stem/proliferative cell compartment and differentiated cell zone." This invention details a method of producing tissue constructs that include distinct regions, each with different cell populations. This innovative approach allows for the creation of two-dimensional in vitro intestinal models that are conducive to rapid imaging and studying the effects of pharmaceuticals, nutraceuticals, and metabolites on intestinal cells.

Another significant patent is related to "Devices, systems, and apparatuses for generating self-sustaining hypoxic conditions and gaseous and non-gaseous chemical gradients for in vitro cell culture." This invention introduces devices and methods for creating gaseous and non-gaseous gradients across cell support structures, which enhance the cultivation of cells or tissues under hypoxic conditions. Such advancements are crucial for better understanding cell behaviors and responses in a controlled environment.

Career Highlights

Nancy has made substantial strides in her academic and professional career, primarily collaborating with prestigious institutions such as the University of California and the University of North Carolina at Chapel Hill. Her work has not only led to groundbreaking inventions but has also advanced the field of biomedical research.

Collaborations

Throughout her career, Nancy has had the opportunity to work alongside esteemed colleagues such as Christopher E. Sims and Yuli Wang. These collaborations have contributed to the development of innovative tissue engineering and cell culture techniques, further amplifying the impact of her research and patents.

Conclusion

Nancy L. Allbritton's outstanding inventions and her commitment to advancing biomedical engineering illustrate her vital role in the scientific community. Her innovative approaches to tissue culture and cell modeling continue to inspire research that could significantly affect health care and medical treatments in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…